Mesoblast gains on FDA nod to review lead drug candidate

Mesoblast

08/03/2023 12:06

** U.S.-listed shares of Australian drug developer Mesoblast
Ltd  MESO.O  rise ~14% to $3.45 before the bell
    ** Australia-listed shares  MSB.AX  also rallied over 23% on
Wednesday
    ** MESO says U.S. FDA agreed to review company's resubmitted
marketing application for its investigational therapy
remestemcel-L
    ** Remestemcel-L is for treatment of the graft-versus-host
disease in children which occurs due to complications after bone
marrow transplants
    ** Currently, there are no approved treatments for this
condition in the United States for children under 12
    ** The U.S. health regulator is set to decide on the use of
MESO's drug by Aug. 2
    ** As of last close, MESO up ~4% so far this year

    
   

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))